TG Therapeutics Strategy and Business Model

Executive Overview

TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell-mediated diseases, with its business centered on BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for adults with relapsing forms of multiple sclerosis. As of FY2024 and early 2025, TG Therapeutics’ strategy was unusually concentrated for a public biotech: build one neurology franchise aggressively in the U.S., extend that asset through lifecycle management such as a subcutaneous formulation, and use partnerships rather than a large owned infrastructure for much of the ex-U.S. opportunity. That makes TG Therapeutics look less like a diversified biotech platform and more like a focused specialty-biopharma launch story. The company traces its roots to 1993 and is headquartered in Morrisville, North Carolina. Its direct commercial footprint is primarily U.S.-based, while international expansion has been pursued through licensing partners. By FY2024, TG Therapeutics had crossed into the more-than-$300 million annual revenue range, with results driven overwhelmingly by BRIUMVI. Strategically, the company’s future is tied to continued share gains in multiple sclerosis, durable payer access, reliable biologics supply, and the success of BRIUMVI lifecycle extensions.

TG Therapeutics at a Glance

Logo
Common name	TG Therapeutics
Full legal name	TG Therapeutics, Inc.
Headquarters	Morrisville, North Carolina, United States
Ownership	Public company (Nasdaq: TGTX)
Ticker	TGTX
Exchange	NASDAQ
Market Cap	$8.28B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Corporate roots date to 1993; company adopted the TG Therapeutics name in 2012; UKONIQ was approved in 2021 and withdrawn in 2022; BRIUMVI was approved in late 2022 and launched in 2023.
Industry or industries	Biopharmaceuticals; neuroimmunology; multiple sclerosis therapies; monoclonal antibodies
Key products or services	BRIUMVI for relapsing multiple sclerosis; partner-led ex-U.S. licensing economics; development-stage lifecycle programs around ublituximab
Geographic footprint	Direct commercial focus in the United States, with international expansion supported through licensing and commercialization partners
Business segments as officially reported	One reportable segment
Company website	https://www.tgtherapeutics.com/

1. What Is the Strategy of TG Therapeutics?

As of FY2024 and early 2025, TG Therapeutics’ public statements point to a focused strategy built around one commercial franchise: BRIUMVI in relapsing multiple sclerosis. Using the Playing to Win framework, the company’s strategy is clearer than that of many small biotechs because it is concentrated, product-led, and execution-dependent.

1a. What is the winning aspiration of TG Therapeutics?

TG Therapeutics’ winning aspiration is to become a durable leader in B-cell-mediated disease treatment by turning BRIUMVI into a major multiple sclerosis franchise and then extending that asset intelligently. The company has described itself as a fully integrated biopharmaceutical company focused on B-cell diseases, but the practical near-term definition of winning is narrower: drive sustained BRIUMVI adoption, convert launch momentum into recurring cash generation, and prove that the company can operate successfully as a commercial neurology company rather than a development-stage biotech. Public disclosures have emphasized annual revenue guidance and commercial execution more than a distant, broad platform vision, which suggests that management’s operating aspiration is commercial scale and franchise durability rather than simply pipeline breadth.
1b. Where does TG Therapeutics play?

TG Therapeutics plays primarily in adult relapsing multiple sclerosis, especially in the U.S. specialty-neurology market. More specifically, it competes in the high-efficacy disease-modifying therapy segment, where anti-CD20 therapies are important. It does not try to cover the full neurology market, all autoimmune diseases, or a broad oncology portfolio. Geographically, its main direct commercial play is the United States; outside the U.S., it has favored partnerships rather than building full local infrastructures. That means its chosen field of play is concentrated by indication, customer type, and geography.
1c. How does TG Therapeutics plan to win?

TG Therapeutics appears to plan to win through a combination of clinical credibility, administration convenience, focused commercial execution, and lifecycle extension. BRIUMVI’s positioning benefits from anti-CD20 efficacy and a relatively short one-hour maintenance infusion after the initial doses. That gives the company a practical message in a market where convenience, infusion-center throughput, and patient preference matter alongside efficacy and safety. TG Therapeutics also appears to be pursuing a disciplined “few things well” model: concentrate sales and marketing on neurologists and multiple sclerosis centers, invest heavily in market access and patient support, and develop a subcutaneous version to improve convenience and defend the franchise over time. In other words, it is trying to win through focused differentiation rather than broad portfolio scale.
1d. What capabilities must TG Therapeutics have in place?

The company needs five capabilities in particular. First, it needs strong specialty commercialization in neurology, including targeted sales coverage of prescribers and infusion sites. Second, it needs sophisticated payer and reimbursement execution, because access, prior authorizations, and site-of-care economics can determine real-world uptake. Third, it needs reliable biologics manufacturing and supply-chain management through third parties, since BRIUMVI is a monoclonal antibody and TG Therapeutics does not rely on a large owned manufacturing network. Fourth, it needs high-quality medical affairs, pharmacovigilance, and regulatory compliance. Fifth, it needs selective clinical development capability to advance formulation changes and possible lifecycle expansion without overextending capital.
1e. What management systems does TG Therapeutics require?

Because TG Therapeutics is a single-product commercial biotech as of FY2024, it requires management systems that are tighter and more operationally data-driven than those of an early research company. Critical systems include salesforce and account-management metrics, gross-to-net pricing analytics, patient start and persistence tracking, inventory and supply planning, pharmacovigilance reporting, medical and promotional compliance, and disciplined cash forecasting. The company also needs stage-gated capital allocation: commercial investments and R&D spending have to be judged against their impact on BRIUMVI adoption, franchise durability, and liquidity. In a business this concentrated, management systems are not back-office detail; they are part of the strategy itself.

2. What Are the Current Strategic Initiatives of TG Therapeutics?

Based on FY2024 disclosures and management commentary into early 2025, TG Therapeutics’ current strategic initiatives are highly specific.

Scale BRIUMVI in U.S. relapsing multiple sclerosis.
The company’s top priority is continued patient-start growth, broader neurologist adoption, and increased use in switches from other disease-modifying therapies. This is the core revenue engine.
Deepen payer access and reduce friction in treatment initiation.
For an infused specialty biologic, formulary coverage, prior authorization success, site-of-care approval, and patient onboarding all matter. TG Therapeutics has devoted substantial attention to access and support infrastructure because commercial execution in this category is often constrained by process, not just demand.
Advance subcutaneous BRIUMVI.
Management has publicly discussed development of a subcutaneous version of BRIUMVI. Strategically, this matters because it could broaden convenience, improve competitiveness against self-administered and faster-administered alternatives, and extend the life of the franchise. As of early 2025, this remained a development initiative rather than an approved product.
Expand internationally through partners rather than a full direct build-out.
TG Therapeutics has pursued licensing and commercialization partnerships for markets outside the United States, including Europe. This lowers fixed cost and execution complexity compared with building country-by-country affiliates.
Operate with commercial discipline.
The company’s public messaging has increasingly emphasized profitability, cash generation, and measured investment. That is strategically important because TG Therapeutics is no longer judged mainly as a clinical-stage biotech; it is judged on commercial conversion.

3. What Is the Business Model of TG Therapeutics?

TG Therapeutics’ business model is straightforward but concentrated. Customers are ultimately buying a high-efficacy disease-modifying therapy for relapsing multiple sclerosis, with the practical promise of anti-CD20 treatment delivered through a relatively efficient infusion experience. The company monetizes that through U.S. product sales and, outside the U.S., through licensing economics such as milestones, transfer pricing, royalties, or other partner-related revenue streams where applicable.

The model is highly repeat-driven. Multiple sclerosis is a chronic disease, and BRIUMVI is administered on an ongoing schedule after the initial doses. That means patient persistence and the pace of new patient starts matter more than one-time transactions. In economic terms, a successful patient start can create annuity-like revenue over time, subject to discontinuation, switching, or safety-related interruptions.

Pricing power exists, but it is constrained. Specialty biologics can command premium pricing because of clinical value and complexity, yet real realized price depends on rebates, discounts, government program rules, and payer negotiations. TG Therapeutics therefore has some list-price leverage but not unconstrained pricing freedom.

The business mix matters because TG Therapeutics is effectively a single-franchise company as of FY2024. There is limited diversification across products, end markets, or channels. That amplifies upside from strong BRIUMVI adoption, but it also increases risk from competitive pressure, reimbursement changes, supply issues, or safety events.

Gross margin is driven by biologics manufacturing economics, royalty or license obligations, inventory scale, and gross-to-net deductions. Operating margin is driven mainly by sales and marketing spend, market access costs, medical affairs, and selective R&D. Cash generation can improve quickly if revenue scales because capital expenditure needs are relatively modest in an outsourced biopharma model.

4. What Products and/or Services Does TG Therapeutics Sell?

As of FY2024, TG Therapeutics’ commercial story is centered overwhelmingly on one product.

BRIUMVI (ublituximab-xiiy).
This is TG Therapeutics’ flagship and revenue-driving product. It is an anti-CD20 monoclonal antibody approved in the United States for adults with relapsing forms of multiple sclerosis. It is strategically important not just because it is the main product, but because it is effectively the company’s franchise platform.
Partner-related ex-U.S. commercialization economics.
In markets where TG Therapeutics has licensed rights rather than built a direct sales organization, it can earn revenue through partnership structures rather than full direct product sales. This is economically important, though still secondary to the U.S. BRIUMVI business.
Development-stage lifecycle programs.
The most important growth-oriented program publicly associated with the franchise is subcutaneous BRIUMVI. This is strategically important even though it is not yet a marketed product, because it could influence convenience, channel mix, and competitive positioning.

TG Therapeutics does not have a broad marketed portfolio. Its prior oncology product UKONIQ was withdrawn in 2022, so the company’s current revenue and strategic emphasis sit squarely with BRIUMVI and related lifecycle work.

5. What Are the Key Competitors or Peers of TG Therapeutics?

TG Therapeutics competes primarily in the relapsing multiple sclerosis disease-modifying therapy market. The most direct competitive pressure comes from other high-efficacy therapies, especially anti-CD20 products.

Roche / Genentech – Ocrevus and related franchise extensions.
This is the most important competitive benchmark. Ocrevus has deep physician familiarity, large installed share, and a broad commercial infrastructure. It is the closest large-scale anti-CD20 franchise comparator.
Novartis – Kesimpta.
Kesimpta is a self-administered anti-CD20 therapy. It competes directly for many of the same patients but offers a different administration model, which is strategically significant.
Biogen – Tysabri and natalizumab-based competition.
Tysabri remains a high-efficacy option in relapsing multiple sclerosis, although its risk profile and treatment logistics differ materially from BRIUMVI.
Merck KGaA / EMD Serono – Mavenclad.
Mavenclad is an oral immune reconstitution therapy that competes as an alternative high-efficacy treatment path.
Bristol Myers Squibb – Zeposia.
Zeposia is an oral therapy and competes more as a substitute than as a direct anti-CD20 equivalent.
Biogen – Vumerity and the fumarate category.
These therapies tend to sit in a different efficacy-convenience position but still matter because prescribers and patients weigh oral options against infusion treatments.
Sanofi – Aubagio.
Aubagio is older and generally not the most direct current comparator, but it remains relevant historically because BRIUMVI’s pivotal trials were measured against teriflunomide.
Johnson & Johnson – Ponvory.
Another oral alternative in the broader relapsing multiple sclerosis treatment landscape.

The most important competitive fact is not the length of the list; it is that TG Therapeutics is challenging far larger companies with broader neurology infrastructures. Its practical fight is for prescribing share, switching share, and anti-CD20 positioning.

6. What Is the Marketing Strategy of TG Therapeutics?

TG Therapeutics’ marketing strategy is best understood as specialty pharmaceutical commercialization, not broad consumer brand building. The central audience is neurologists, multiple sclerosis specialists, infusion sites, and payers. Patients matter, but the main commercial bottlenecks are physician confidence, access, and treatment logistics.

The company’s message architecture appears to revolve around three ideas: clinical efficacy, the anti-CD20 mechanism, and administration convenience, especially the one-hour maintenance infusion after initiation. In this market, that kind of message can be meaningful because it affects infusion-center capacity, patient scheduling, and treatment experience.

Marketing likely depends heavily on:

targeted field promotion to prescribing neurologists and key treatment centers;
medical affairs engagement and conference presence to reinforce clinical credibility;
payer and access communications to reduce reimbursement friction; and
patient services and support programs that help move a prescription to an administered therapy.

Marketing is important, but it is not the core differentiator by itself. In TG Therapeutics’ case, marketing mainly amplifies product attributes and access execution. Clinical evidence, reimbursement, and site-of-care economics remain more decisive than brand advertising in the usual consumer sense.

7. What Are the Key Customer Segments of TG Therapeutics?

TG Therapeutics has a relatively narrow but layered customer set.

Neurologists and multiple sclerosis specialists.
These are the key prescribers and the most important decision-makers in product selection.
Infusion centers, hospital outpatient departments, and physician-administered sites of care.
Because BRIUMVI is an infused therapy, treatment sites are operationally important customers and influencers.
Payers, pharmacy benefit managers, and government reimbursement programs.
These stakeholders strongly affect formulary status, prior authorization requirements, site-of-care approvals, and realized net price.
Specialty distributors and specialty pharmacies.
These are direct channel customers in many cases, even though they are not the ultimate clinical decision-makers.
Patients with relapsing multiple sclerosis.
They are the end users, and patient preference around convenience, access, and support can influence therapy choice and persistence.
International commercialization partners.
Outside the U.S., partners can function as customers for rights, supply, or alliance economics, depending on the structure.

TG Therapeutics is not diversified by end market in the way a larger pharmaceutical company would be. As of FY2024, its economics were heavily concentrated in one disease area and one product, which increases both focus and risk.

8. What Is the Sales Model of TG Therapeutics?

In the United States, TG Therapeutics uses a specialty-biopharma sales model. It sells BRIUMVI through a limited, specialized channel rather than broad retail distribution, and demand creation is handled by a targeted field organization calling on neurologists, multiple sclerosis centers, and relevant infusion sites.

The channel structure matters. Because BRIUMVI is provider-administered, the company must win not only at the prescriber level but also at the reimbursement and administration level. This means the sales model has several layers:

field sales to prescribers and treatment centers;
market access and contracting with payers;
hub and patient-support services that help with benefits verification and onboarding;
specialty distribution and specialty pharmacy relationships; and
medical affairs support that reinforces scientific confidence.

Outside the U.S., the model is more partner-led. That lowers fixed cost and can accelerate geographic reach, but it also means TG Therapeutics gives up some direct commercial control in exchange for a leaner structure.

For consultants, this kind of channel architecture often creates opportunities in territory design, site-of-care strategy, patient journey redesign, gross-to-net analytics, and partner-management support.

9. In What Geographies Does TG Therapeutics Operate?

TG Therapeutics’ direct operating footprint is centered on the United States, where it runs the core BRIUMVI commercial effort. That is the company’s most important market by revenue, infrastructure, and management attention as of FY2024.

Operationally, the company is headquartered in North Carolina, while its commercial, medical, and corporate activities support a nationwide U.S. specialty-neurology business. Unlike a large multinational pharmaceutical company, TG Therapeutics does not have a broad owned global network of manufacturing plants, sales affiliates, or distribution centers.

Internationally, TG Therapeutics has pursued a partnership model. Public disclosures indicate ex-U.S. commercialization arrangements, including in Europe, rather than a full direct-country build-out. This matters strategically because it allows the company to participate in international markets without taking on the fixed cost base of a large global organization.

In short, TG Therapeutics is geographically commercially focused rather than globally built out: strong concentration in the U.S., with selective international reach through partners.

10. Who Are the Owners of TG Therapeutics?

TG Therapeutics is a publicly traded company listed on Nasdaq under the ticker TGTX. As of early 2025 public disclosures, ownership appeared broadly distributed across institutional investors and insiders rather than concentrated in a single controlling shareholder.

Large outside holders in companies of this type commonly include major asset managers such as BlackRock and The Vanguard Group, with ownership levels changing over time based on 13F filings and index activity. TG Therapeutics has also historically had meaningful insider ownership, including by senior management. No majority owner or obvious controlling stake is central to the current equity story.

11. How Is TG Therapeutics Organized?

As of FY2024, TG Therapeutics reported one reportable segment. That is an important fact: despite the scientific complexity of biotech, the company is not organized financially as a portfolio of multiple major business lines.

At a practical level, the company appears organized around core specialty-biopharma functions:

commercial and sales;
market access and patient services;
medical affairs and pharmacovigilance;
clinical development and regulatory affairs;
technical operations and external manufacturing management; and
corporate functions such as finance, legal, and investor relations.

Legally, it is a single public parent company with subsidiaries and contractual partner relationships. Operationally, it behaves more like a lean franchise company than a diversified pharmaceutical holding company. The reporting structure is therefore simpler than the economics: official reporting is one segment, but internally the business likely has to manage distinct workflows across commercialization, development, and external supply.

12. How Does TG Therapeutics Operate?

Day to day, TG Therapeutics operates as a specialty commercial biotech with outsourced industrial infrastructure. It does not win by running factories at scale; it wins by coordinating science, access, supply, and commercialization effectively.

The main operating activities that create value are:

forecasting demand for BRIUMVI and coordinating supply with external manufacturers;
maintaining quality systems, regulatory compliance, and safety reporting;
driving physician adoption through a targeted neurology field force;
securing and maintaining payer coverage;
helping patients move through benefits verification, scheduling, and treatment initiation; and
running lifecycle development programs that can protect or expand the franchise.

The main operational bottlenecks are not generic. They include reimbursement friction, site-of-care complexity, the logistics of an infused biologic, channel inventory planning, and dependence on third parties for manufacturing and distribution. Because the company is concentrated in one major product, any breakdown in one of these operating areas can have an outsized impact on financial performance.

13. What Are the Growth Opportunities for TG Therapeutics?

The most plausible growth opportunities for TG Therapeutics are closely tied to the BRIUMVI franchise.

Further penetration of the U.S. relapsing multiple sclerosis market.
This is the clearest opportunity. If TG Therapeutics can continue winning new patient starts and switches, the installed base can compound because therapy is repeat-driven.
Share gains within the anti-CD20 category.
The company does not need to dominate all multiple sclerosis therapies to grow meaningfully; it can grow by taking incremental share in a clinically important treatment class.
Subcutaneous BRIUMVI.
If successfully developed and approved, a subcutaneous option could improve convenience, expand competitive flexibility, and strengthen lifecycle economics.
International expansion through partners.
Partner-led commercialization can add royalty or milestone streams without requiring a large direct commercial build-out.
Potential expansion into additional B-cell-mediated indications.
This is more of a strategic possibility than a fully de-risked near-term fact. It is plausible because the mechanism is relevant beyond relapsing multiple sclerosis, but investors should distinguish clearly between logical opportunity and approved use.

The main constraints are equally clear: powerful incumbents, payer controls, single-product concentration, manufacturing dependence on third parties, and the normal regulatory and safety risks that come with biologics.

14. What Is the History of TG Therapeutics?

TG Therapeutics’ corporate lineage dates to 1993, although the company in its current form emerged through later strategic repositioning rather than a simple founder-led startup narrative. Public materials emphasize the company’s lineage and transformation more than a single founder identity.

The modern TG Therapeutics story was shaped in the early 2010s, when the company adopted the TG Therapeutics name and focused on therapies targeting B-cell biology. For several years, its identity was tied largely to hematologic malignancies, including development of umbralisib and ublituximab-based programs.

A major milestone came in 2021, when the U.S. Food and Drug Administration approved UKONIQ for certain B-cell malignancies. But that success did not last. In 2022, following safety concerns and a strategic reassessment, TG Therapeutics voluntarily withdrew UKONIQ and effectively reset the company.

That same year, the company secured what became the defining event in its current history: FDA approval of BRIUMVI for adults with relapsing forms of multiple sclerosis in late 2022. The U.S. launch followed in 2023, and by FY2024 the company had become a commercially focused multiple sclerosis company rather than an oncology-focused development story. That pivot is the central fact in understanding TG Therapeutics today.

15. What Are the Key Suppliers to TG Therapeutics?

Suppliers matter strategically to TG Therapeutics because the company is a commercial biotech without a large owned manufacturing base. The most important supplier categories are:

Contract manufacturing organizations that handle drug substance production, fill-finish, packaging, and related biologics processes;
raw material and component suppliers used in monoclonal antibody manufacturing and packaging;
quality, testing, and logistics providers that support release, storage, and transportation; and
contract research and development partners that support ongoing clinical and formulation work.

Public filings for companies like TG Therapeutics typically emphasize dependence on third-party manufacturers and service providers, including situations where alternative sources may be limited or would take time to qualify. That supplier structure matters more here than it would in a diversified pharmaceutical company, because a disruption can hit a single-franchise business directly and immediately.

16. How Does the Supply Chain of TG Therapeutics Function?

TG Therapeutics’ supply chain is built around the realities of a commercial biologic. Upstream, the company relies on third parties for manufacturing, fill-finish, packaging, and quality-release processes. Midstream, it must manage storage, inventory planning, and distribution in a manner consistent with biologics handling requirements. Downstream, product moves through a specialized channel to sites that administer the therapy.

Several supply-chain activities are especially important:

demand forecasting tied to patient starts and ongoing dosing schedules;
coordination with external manufacturers on capacity, batch timing, and quality release;
inventory management that avoids both shortages and excess channel stock;
specialty distribution and pharmacy coordination; and
support for infusion-site administration and patient scheduling.

Supply-chain reliability is strategically important because BRIUMVI is not a convenience-store product that can absorb disruption quietly. If supply is interrupted, the company risks treatment delays, prescriber frustration, and lost credibility in a market where neurologists already have established alternatives.

17. What Is the R&D Strategy of TG Therapeutics?

R&D remains important at TG Therapeutics, but the company’s approach as of FY2024 looks more focused and franchise-oriented than broad-platform in nature. The central R&D priority is not a sprawling discovery engine across many modalities; it is the extension and strengthening of the BRIUMVI franchise.

The clearest example is the development of subcutaneous BRIUMVI. This is not just a formulation exercise. Strategically, it is a competitive R&D program intended to improve convenience, preserve relevance as the multiple sclerosis market evolves, and potentially broaden channel flexibility.

TG Therapeutics’ R&D model also appears relatively lean. Like many smaller biopharma companies, it relies on external partners and service providers for parts of development and manufacturing rather than owning every capability internally. That allows the company to target investment where it sees the best risk-adjusted commercial return.

After the 2022 reset around UKONIQ, TG Therapeutics’ R&D strategy appears more disciplined: fewer bets, closer to commercial relevance, and more directly linked to what can sustain the current franchise.

18. What Is the Finance Strategy of TG Therapeutics?

TG Therapeutics’ finance strategy has shifted materially as the company moved from development-stage biotech to commercial operator. Historically, small biopharma companies are judged on access to capital and pipeline progress. As of FY2024, TG Therapeutics increasingly had to prove a different set of capabilities: revenue scaling, expense discipline, and cash generation.

At a high level, the company’s finance strategy appears to support three priorities:

fund the BRIUMVI launch and market expansion without letting operating costs outrun the franchise;
invest selectively in lifecycle R&D, especially programs with a clear strategic link to the core asset; and
maintain balance-sheet flexibility in a business where product concentration raises risk.

The economics of the model can be attractive if scale is achieved. Biologic specialty drugs can carry strong gross margins, while outsourced manufacturing keeps capital expenditure relatively low. That creates potential operating leverage as revenue grows. The offset is that gross-to-net deductions, commercial infrastructure, patient support, medical affairs, and continued development spending can all pressure profitability if growth slows.

In practical terms, finance strategy at TG Therapeutics is inseparable from commercial strategy: the faster BRIUMVI becomes a larger recurring franchise, the more self-funded and strategically flexible the company becomes.

19. How Companies Like TG Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like TG Therapeutics use Umbrex when they want the rigor and functional depth associated with top-tier consulting, but do not need a full consulting team with the overhead of a major firm. For a focused commercial biotech such as TG Therapeutics, that can be especially relevant because strategic needs are real, but management often wants targeted expertise, speed, and flexibility.

Representative projects Umbrex consultants can support for a company like TG Therapeutics include:

U.S. multiple sclerosis market segmentation and prescriber-switch analysis to refine where BRIUMVI should invest most heavily for share gains.
Sales force sizing, territory design, and call-plan optimization for neurologists, infusion centers, and key multiple sclerosis treatment hubs.
Payer access strategy and gross-to-net analytics, including prior authorization bottleneck analysis and site-of-care reimbursement optimization.
Patient journey redesign for onboarding, benefits verification, infusion scheduling, and persistence support.
Launch readiness planning and commercialization strategy for a future subcutaneous BRIUMVI formulation.
International partner strategy, including market prioritization, partner selection support, and alliance-management operating model design.
Supply-chain risk assessment for a single-product biologics franchise, including contingency planning around contract manufacturing concentration.
Commercial operating model redesign to align medical affairs, market access, patient services, and field teams as the franchise scales.
Lifecycle management business cases for additional B-cell-mediated indications or formulation investments.
Finance and scenario modeling projects covering revenue build, operating leverage, cash planning, and capital allocation choices for a focused commercial biotech.